Vutrisiran can improve and maintain functional capacity and quality of life in patients with transthyretin amyloidosis with ...

Alnylam Pharmaceuticals ALNY -3.78% Get Free Report has outperformed the market over the past 15 years by 8.52% on an ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Alnylam Pharmaceuticals, Inc.’s ALNY share price has dipped by 10.08%, which has investors questioning if this is right time ...

Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 analysts. The following table summarizes their recent ratings, shedding light ...

We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Research analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for Alnylam Pharmaceuticals in a ...

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) on April 3 and set a price target of $330.00.